<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id>
      <journal-title-group>
        <journal-title>BMC Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2377</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20482768</article-id>
      <article-id pub-id-type="pmc">2880963</article-id>
      <article-id pub-id-type="publisher-id">1471-2377-10-32</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2377-10-32</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Naess</surname>
            <given-names>Halvor</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>haln@haukeland.no</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Glad</surname>
            <given-names>Solveig</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>sgla@haukeland.no</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Storstein</surname>
            <given-names>Anette</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>astt@haukeland.no</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Rinaldo</surname>
            <given-names>Christine H</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>Christine.Hanssen.Rinaldo@unn.no</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>M&#xF8;rk</surname>
            <given-names>Sverre J</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>svjm@haukeland.no</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Myhr</surname>
            <given-names>Kjell-Morten</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>kjmy@haukeland.no</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Hirsch</surname>
            <given-names>Hans</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>Hans.Hirsch@unibas.ch</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Neurology, Haukeland University Hospital, N-5021 Bergen, Norway</aff>
      <aff id="I2"><label>2</label>Department of Microbiology and Infection Control, University Hospital of North Norway, N-9038 Troms&#xF8;, Norway</aff>
      <aff id="I3"><label>3</label>Department of Pathology, Haukeland University Hospital, N-5021 Bergen, Norway</aff>
      <aff id="I4"><label>4</label>Div. Molecular Diagnostics, Clinical &amp; Transplantation Virology, Institute for Medical Microbiology, Petersplatz 10, CH-4003 Basel, Switzerland</aff>
      <pub-date pub-type="collection">
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>5</month>
        <year>2010</year>
      </pub-date>
      <volume>10</volume>
      <fpage>32</fpage>
      <lpage>32</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>11</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>5</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2010 Naess et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2010</copyright-year>
        <copyright-holder>Naess et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2377/10/32"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>To report the clinical course of PML in an apparently immunocompetent patient treated with cidofovir.</p>
        </sec>
        <sec>
          <title>Case Presentation</title>
          <p>A 35-year-old immunocompetent man who developed progressive hemianopsia, aphasia, and limb weakness underwent repeated MRI scans of the brain, spinal fluid analyses, and brain biopsy. Before diagnosis was established based on brain biopsy, he was consecutively treated with methylprednisolone, acyclovir, ceftriaxone and plasmapheresis, but he deteriorated rapidly suggestive of the immune reconstitution inflammatory syndrome (IRIS). He started to recover two weeks after the initiation of treatment with cidofovir and has had no relapse at 3 1/2 years of follow-up. MRI has shown marked improvement.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>PML should be considered in immunocompetent patients with a typical clinical course and MRI findings compatible with PML. Treatment with cidofovir should be considered as early as possible in the disease course.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Progressive multifocal leukoencephalopathy (PML) which is caused by the JC virus (JCV), is a rare and usually fatal demyelinating disease of the central nervous system typically occurring in severely immunosuppressed patients [<xref ref-type="bibr" rid="B1">1</xref>]. The diagnosis of PML is presumptive when based on clinical or radiological evidence and the detection of JCV DNA by polymerase chain reaction (PCR) in the cerebrospinal fluid (CSF). The diagnosis is definitive by detection of viral protein or DNA by immunohistochemistry or <italic>in situ </italic>hybridisation of brain biopsies, respectively. While the JCV genomes of urine isolates usually have an archetypal regulatory region, genomes detected in the CSF and brains from PML patients have always a rearranged viral regulatory region. Even though the majority of PML cases are found in HIV infected patients, cases have been diagnosed in patients with other cellular immunodeficiencies due to haematological malignancy, chemotherapy, organ transplantation, lymphocyte depletion as well as systemic lupus erythematosus [<xref ref-type="bibr" rid="B1">1</xref>]. Increasing occurrence of PML in patients exposed to monoclonal antibody therapy such as natalizumab [<xref ref-type="bibr" rid="B2">2</xref>], rituximab [<xref ref-type="bibr" rid="B3">3</xref>], and efalizumab have been reported [<xref ref-type="bibr" rid="B4">4</xref>].</p>
      <p>PML is often fatal [<xref ref-type="bibr" rid="B5">5</xref>], but prolonged survival has been reported during antiviral treatment with cidofovir [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. No definitive guidelines for treatment of PML have been established. The treatment is often complicated by the immune reconstitution inflammatory syndrome (IRIS) [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. We report an immunocompetent man with PML probably complicated with IRIS who was successfully treated with cidofovir.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 35-years-old man was admitted to the Department of Neurology, Haukeland University Hospital in Bergen, Norway because of increasing problems with reading during the last four weeks. Apart from surgery for appendicitis 16 years earlier the patient was previously healthy. On admission, the neurological examination was normal except for a bilateral lower right-sided quadrant anopsia.</p>
      <p>Magnetic resonance imaging (MRI) showed occipital white matter lesions mainly on the left side (Figure <xref ref-type="fig" rid="F1">1A</xref>). CSF analyses were normal (PCR on JCV was not performed). Extensive haematological and immunological blood analyses were performed including electrolytes, creatinine, liver enzymes, and CRP and they were all normal. The patient remained HIV negative on repeated tests.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>MRI on admission and follow-up</bold>. A. MRI (flair T2) performed on admission showing a white matter lesion in the parieto-occipital region on the left side. B. MRI (flair T2) showing progression of the white matter lesion 10 days after admission. C. MRI (flair T2) showing progression of the white matter lesions in both hemipheres 3 1/2 weeks after onset of treatment with cidofovir. D. MRI (flair T2) shower regression of the white matter lesions in both hemispheres 6 months after onset of treatment with cidofovir.</p>
        </caption>
        <graphic xlink:href="1471-2377-10-32-1"/>
      </fig>
      <p>Ten days after admission the patient had developed a complete bilateral right-sided hemianopsia and slight bilateral left-sided quadrant anopsia. A new MRI showed progression of the white matter lesions (Figure <xref ref-type="fig" rid="F1">1B</xref>). The patient was consecutively treated with high dose methylprednisolone, acyclovir, ceftriaxone and plasmapheresis. However, the vision disturbances progressed and he also developed aphasia and paresis of the right arm. Four weeks after admission brain biopsy was taken from the left occipital lobe lesion. Histology showed demyelination and atypical astrocytes suggestive of PML (Figure <xref ref-type="fig" rid="F2">2A-D</xref>). PCR performed on extracted DNA from brain biopsy specimens was strongly positive for JCV. Retrospective quantitative PCR analysis of the original CSF was performed [<xref ref-type="bibr" rid="B13">13</xref>] and showed 2500 JCV genome copies/ml. Sequencing analysis of the JCV genome [<xref ref-type="bibr" rid="B14">14</xref>] showed a highly rearranged unique non-coding control region denoted PML HL (Figure <xref ref-type="fig" rid="F3">3</xref>). Retrospective enzyme immunoassay serum analysis (EIA) [<xref ref-type="bibr" rid="B14">14</xref>] showed JCV IgG antibodies at the time of hospitalization and the titres gradually increased at 3-months of follow-up. However, the JCV IgM levels were low and constant (Figure <xref ref-type="fig" rid="F4">4</xref>).</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Brain biopsy</bold>. The biopsy specimen contained cortical grey and subcortical white matter with loose tissue texture (edema), fine caliber vacuolization, swollen, reactive astrocytes (pink cytoplasm in Panel A, hematoxylin and eosin), microglia and lipid macrophages (transformed microglia). Large pleomorphic nuclei of some astrocytes are clearly evidenced. Immunohistochemical staining for myelin basic protein (Panel B, immunoperoxidase (brown)) shows loss of myelin in the white matter lesion. Pleomorphic cells are immunopositive for astrocyte marker glial fibrillary acidic protein (Panel C, immunoperoxidase for GFAP). In-situ-hybridization of the demyelinated lesion (Panel D, original magnification &#xD7;400) shows enlarged irregular nuclei positive for JC virus.</p>
        </caption>
        <graphic xlink:href="1471-2377-10-32-2"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Sequencing analysis of the JCV genome</bold>. Schematic illustration of the archetype JCV regulatory regions/NCCR found in the urine of healthy people and the rearranged regulatory region demonstrated by the PCR in the CSF of the PML patient.</p>
        </caption>
        <graphic xlink:href="1471-2377-10-32-3"/>
      </fig>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <p><bold>JCV and BKV antibody titres</bold>. JCV and BKV virus-like particle (VLP)-specific IgG levels from the time of patient administration and the following 16 months. The data were obtained retrospectively by EIA. OD 492 nm, optical density at 492 nm.</p>
        </caption>
        <graphic xlink:href="1471-2377-10-32-4"/>
      </fig>
      <p>Treatment with intravenous cidofovir was initiated five weeks after admission. The patient received 350 mg once a week for three weeks and thereafter every fortnight for 6 months. Two weeks after onset of treatment with cidofovir the patient reported some improvement of the paresis in his right arm. Yet the MRI (Figure <xref ref-type="fig" rid="F1">1C</xref>) performed after 3 1/2 weeks treatment showed further progression compared with the MRI performed 2 weeks prior to onset of treatment with cidofovir. However, the patient continued to improve clinically, and he recovered completely from the paresis of his right arm and aphasia. After two months of treatment he also reported slight improvement of his vision.</p>
      <p>MRI performed after 4 months of treatment showed marked regression of the white matter lesions. The patient's vision improved slightly during the next months, and the MRI (Figure <xref ref-type="fig" rid="F1">1D</xref>) showed further improvement after 6 months. The white matter lesions remained unaltered on further MRI investigations, the last one being performed 30 months after onset of treatment with cidofovir. Follow-up PCR analysis of the CSF was JCV negative seven months after onset of treatment with cidofovir.</p>
      <p>The patient developed epilepsy 9 months after onset of symptoms.</p>
      <p>Antinuclear antibodies, quantification of immunoglobulins (IgG 17.3 g/liter, IgA (.55 g/liter), IgM (1,3 g/liter), electrophoresis, as well as complement (C3, C4) were all normal, except for moderate reduced levels of IgA (0.55 g/L). The number of CD4 T-cells was 994 &#xD7; 10<sup>6</sup>/liter (normal range 516 - 1494 &#xD7; 10<sup>6</sup>/liter), the number of CD8 T-cells was 271 &#xD7; 10<sup>6</sup>/liter (normal range 306 - 1184 &#xD7; 10<sup>6</sup>/liter), and the number of natural killer cells (CD56) was 2.9 &#xD7; 10<sup>6</sup>/liter (normal range 5.0 - 26.0 &#xD7; 10<sup>6</sup>/liter). The moderately reduced numbers of CD8 T-cells and natural killer cells (CD56) were probably secondary to the treatment with methylprednisolone. It was concluded by immunologiststhat immunodeficiency was unlikely.</p>
      <p>At the last follow-up which was 46 months after the onset of treatment with cidofovir, the patient had experienced no relapse.</p>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>This case report of PML highlights several interesting points. Firstly, apparently immunocompetent persons may develop PML, and secondly, treatment with cidofovir may be successful. Thirdly, the increased progression of symptoms after initiating antiviral and antibiotic therapy, methylprednisolone and plasmapheresis, was suggestive of immune reconstitution inflammatory syndrome (IRIS). This complication may therefore follow PML treatment in apparently immunocompetent persons.</p>
      <p>Clinical improvement within 2 weeks of the onset of cidofovir therapy suggests that cidofovir was effective. However, spontaneous recovery cannot be ruled out [<xref ref-type="bibr" rid="B15">15</xref>]. The progression of the MRI white matter lesions detected 3 1/2 weeks after onset of cidofovir treatment may have been related to disease progression prior to the initiation of cidofovir therapy. Others have reported clinical improvement in spite of initial worsening of lesions on MRI [<xref ref-type="bibr" rid="B16">16</xref>]. The MRI performed 4 months after onset of treatment showed marked improvement.</p>
      <p>The rapid deterioration prior to treatment with cidofovir is suggestive of IRIS. IRIS is usually explained by reconstitution of a compromised immune system, followed by a strong immune response and inflammation. This may lead to a paradoxical clinical worsening of an appropriately treated infection [<xref ref-type="bibr" rid="B17">17</xref>]. IRIS may be seen in HIV positive PML patients who receive antiretroviral therapy [<xref ref-type="bibr" rid="B17">17</xref>]. or in PML patients with immunomodulatory therapy and plasmapheresis for removing the immunosupressing agent [<xref ref-type="bibr" rid="B18">18</xref>]. Our patient received plasmapheresis, and one might speculate whether removing the natural humoral immune response to the JCV could influence the risk of IRIS.</p>
      <p>There are reports that cidofovir may prolong survival among immunocompromised patients with PML [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B19">19</xref>] while others have failed to confirm any effect of treatment with cidofovir [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. One might speculate whether cidofovir is more effective the more immunocompetent the patient is.</p>
      <p>In conclusion, PML should be considered in immunocompetent patients with a typical clinical course and MRI findings compatible with PML. Treatment with cidofovir should be considered as early as possible in the disease course.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>HN investigated, treated the patient and drafted the manuscript. SG investigated the patient and contributed to important revisions of the draft. AS treated the patient and contributed to important revisions of the draft. CHR sequenced the JVC genome, and contributed to important revisions of the draft. SJM performed the histology examinations, selected histology images and contributed to important revisions of the draft. KMM contributed to conception, design and important revisions of the draft. HH performed the JCV antibody analyses. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2377/10/32/prepub">http://www.biomedcentral.com/1471-2377/10/32/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Khanna</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Elzi</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Mueller</surname>
            <given-names>NJ</given-names>
          </name>
          <name>
            <surname>Garzoni</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cavassini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fux</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Vernazza</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bernasconi</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Battegay</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hirsch</surname>
            <given-names>HH</given-names>
          </name>
          <article-title>Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study</article-title>
          <source>Clin Infect Dis</source>
          <year>2009</year>
          <volume>48</volume>
          <issue>10</issue>
          <fpage>1459</fpage>
          <lpage>1466</lpage>
          <pub-id pub-id-type="doi">10.1086/598335</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kappos</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Bates</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hartung</surname>
            <given-names>HP</given-names>
          </name>
          <name>
            <surname>Havrdova</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Polman</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Ravnborg</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hauser</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Rudick</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Weiner</surname>
            <given-names>HL</given-names>
          </name>
          <article-title>Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring</article-title>
          <source>Lancet Neurol</source>
          <year>2007</year>
          <volume>6</volume>
          <issue>5</issue>
          <fpage>431</fpage>
          <lpage>441</lpage>
          <pub-id pub-id-type="doi">10.1016/S1474-4422(07)70078-9</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Carson</surname>
            <given-names>KR</given-names>
          </name>
          <name>
            <surname>Evens</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Richey</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Habermann</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Focosi</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Seymour</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Laubach</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bawn</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Gordon</surname>
            <given-names>LI</given-names>
          </name>
          <name>
            <surname>Winter</surname>
            <given-names>JN</given-names>
          </name>
          <article-title>Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>113</volume>
          <issue>20</issue>
          <fpage>4834</fpage>
          <lpage>4840</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-10-186999</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Carson</surname>
            <given-names>KR</given-names>
          </name>
          <name>
            <surname>Focosi</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Major</surname>
            <given-names>EO</given-names>
          </name>
          <name>
            <surname>Petrini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Richey</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>West</surname>
            <given-names>DP</given-names>
          </name>
          <name>
            <surname>Bennett</surname>
            <given-names>CL</given-names>
          </name>
          <article-title>Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project</article-title>
          <source>Lancet Oncol</source>
          <year>2009</year>
          <volume>10</volume>
          <issue>8</issue>
          <fpage>816</fpage>
          <lpage>824</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70161-5</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Berger</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Major</surname>
            <given-names>EO</given-names>
          </name>
          <article-title>Progressive multifocal leukoencephalopathy</article-title>
          <source>Semin Neurol</source>
          <year>1999</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>193</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2008-1040837</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>De Luca</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Giancola</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Ammassari</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Grisetti</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Cingolani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Paglia</surname>
            <given-names>MG</given-names>
          </name>
          <name>
            <surname>Govoni</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Murri</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Testa</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Monforte</surname>
            <given-names>AD</given-names>
          </name>
          <article-title>Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy</article-title>
          <source>Aids</source>
          <year>2000</year>
          <volume>14</volume>
          <issue>14</issue>
          <fpage>F117</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="doi">10.1097/00002030-200009290-00001</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Viallard</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Lazaro</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ellie</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Eimer</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Camou</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Caubet</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Lafon</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Fleury</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Pellegrin</surname>
            <given-names>JL</given-names>
          </name>
          <article-title>Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis</article-title>
          <source>Infection</source>
          <year>2007</year>
          <volume>35</volume>
          <issue>1</issue>
          <fpage>33</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="doi">10.1007/s15010-006-5103-y</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Viallard</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Lazaro</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Lafon</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Pellegrin</surname>
            <given-names>JL</given-names>
          </name>
          <article-title>Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma</article-title>
          <source>Leuk Lymphoma</source>
          <year>2005</year>
          <volume>46</volume>
          <issue>11</issue>
          <fpage>1659</fpage>
          <lpage>1662</lpage>
          <pub-id pub-id-type="doi">10.1080/10428190500177995</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Roberts</surname>
            <given-names>MT</given-names>
          </name>
          <name>
            <surname>Carmichael</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lever</surname>
            <given-names>AM</given-names>
          </name>
          <article-title>Prolonged survival in AIDS-related progressive multifocal leucoencephalopathy following anti-retroviral therapy and cidofovir</article-title>
          <source>Int J Antimicrob Agents</source>
          <year>2003</year>
          <volume>21</volume>
          <issue>4</issue>
          <fpage>347</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="doi">10.1016/S0924-8579(02)00393-X</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Marra</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Rajicic</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Barker</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Clifford</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Donovan Post</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Ruiz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bowen</surname>
            <given-names>BC</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Queen-Baker</surname>
            <given-names>J</given-names>
          </name>
          <article-title>A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS</article-title>
          <source>Aids</source>
          <year>2002</year>
          <volume>16</volume>
          <issue>13</issue>
          <fpage>1791</fpage>
          <lpage>1797</lpage>
          <pub-id pub-id-type="doi">10.1097/00002030-200209060-00012</pub-id>
          <pub-id pub-id-type="pmid">12218391</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Roda</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ostrow</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>McArthur</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nath</surname>
            <given-names>A</given-names>
          </name>
          <article-title>PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids</article-title>
          <source>Neurology</source>
          <year>2009</year>
          <volume>72</volume>
          <issue>17</issue>
          <fpage>1458</fpage>
          <lpage>1464</lpage>
          <pub-id pub-id-type="doi">10.1212/01.wnl.0000343510.08643.74</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Linda</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>von Heijne</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Major</surname>
            <given-names>EO</given-names>
          </name>
          <name>
            <surname>Ryschkewitsch</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Berg</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Olsson</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Progressive multifocal leukoencephalopathy after natalizumab monotherapy</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>361</volume>
          <issue>11</issue>
          <fpage>1081</fpage>
          <lpage>1087</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0810316</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Drachenberg</surname>
            <given-names>CB</given-names>
          </name>
          <name>
            <surname>Papadimitriou</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Mann</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hirsch</surname>
            <given-names>HH</given-names>
          </name>
          <name>
            <surname>Wali</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ramos</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Negative impact of human leukocyte antigen matching in the outcome of polyomavirus nephropathy</article-title>
          <source>Transplantation</source>
          <year>2005</year>
          <volume>80</volume>
          <issue>2</issue>
          <fpage>276</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1097/01.TP.0000165096.01034.15</pub-id>
          <pub-id pub-id-type="pmid">16041275</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Egli</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Infanti</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Dumoulin</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Buser</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Samaridis</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Stebler</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gosert</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hirsch</surname>
            <given-names>HH</given-names>
          </name>
          <article-title>Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors</article-title>
          <source>J Infect Dis</source>
          <year>2009</year>
          <volume>199</volume>
          <issue>6</issue>
          <fpage>837</fpage>
          <lpage>846</lpage>
          <pub-id pub-id-type="doi">10.1086/597126</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Price</surname>
            <given-names>RW</given-names>
          </name>
          <name>
            <surname>Nielsen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Horten</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Rubino</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Padgett</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Walker</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Progressive multifocal leukoencephalopathy: a burnt-out case</article-title>
          <source>Ann Neurol</source>
          <year>1983</year>
          <volume>13</volume>
          <issue>5</issue>
          <fpage>485</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.410130503</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cinque</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bossolasco</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Brambilla</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Boschini</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mussini</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Pierotti</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Campi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Casari</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bertelli</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mena</surname>
            <given-names>M</given-names>
          </name>
          <article-title>The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature</article-title>
          <source>J Neurovirol</source>
          <year>2003</year>
          <volume>9</volume>
          <issue>Suppl 1</issue>
          <fpage>73</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">12709876</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Meintjes</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Lynen</surname>
            <given-names>L</given-names>
          </name>
          <article-title>Prevention and treatment of the immune reconstitution inflammatory syndrome</article-title>
          <source>Curr Opin HIV AIDS</source>
          <year>2008</year>
          <volume>3</volume>
          <issue>4</issue>
          <fpage>468</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="doi">10.1097/COH.0b013e3282fe6e84</pub-id>
          <pub-id pub-id-type="pmid">19373007</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Langer-Gould</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Atlas</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Bollen</surname>
            <given-names>AW</given-names>
          </name>
          <name>
            <surname>Pelletier</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Progressive multifocal leukoencephalopathy in a patient treated with natalizumab</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <issue>4</issue>
          <fpage>375</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa051847</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cardenas</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>KH</given-names>
          </name>
          <name>
            <surname>Sack</surname>
            <given-names>K</given-names>
          </name>
          <article-title>The effects of cidofovir on progressive multifocal leukoencephalopathy: an MRI case study</article-title>
          <source>Neuroradiology</source>
          <year>2001</year>
          <volume>43</volume>
          <issue>5</issue>
          <fpage>379</fpage>
          <lpage>382</lpage>
          <pub-id pub-id-type="doi">10.1007/s002340000495</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Berenguer</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Miralles</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Arrizabalaga</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ribera</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Dronda</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Baraia-Etxaburu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Domingo</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Marquez</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rodriguez-Arrondo</surname>
            <given-names>FJ</given-names>
          </name>
          <name>
            <surname>Laguna</surname>
            <given-names>F</given-names>
          </name>
          <article-title>Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy</article-title>
          <source>Clin Infect Dis</source>
          <year>2003</year>
          <volume>36</volume>
          <issue>8</issue>
          <fpage>1047</fpage>
          <lpage>1052</lpage>
          <pub-id pub-id-type="doi">10.1086/374048</pub-id>
          <pub-id pub-id-type="pmid">12684918</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
